DAIRY-PROTEIN-DERIVED PEPTIDES WITH ANGIOTENSIN 1 CONVERTING ENZYME INHIBITORY ACTIVITY

• Main Authors: MANZANARES MIR PALOMA, VALLES ALVENTOSA SALVADOR, ENRIQUE LOPEZ MARIA, SALOM SALVANERO JOAN, CENTENO GUIL JOSE MARIA, MARCOS LOPEZ JOSE
• Format: Patent
• Language: English; Spanish
• Published: 12.11.2009
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; FOODS OR FOODSTUFFS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROTEIN COMPOSITIONS FOR FOODSTUFFS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE; WORKING-UP PROTEINS FOR FOODSTUFFS

The invention consists in the use of bioactive products derived from dairy proteins - lactoferrin - and the hydrolyzate of lactoferrin that contains said products. This involves a peptide with fifteen amino acid residues (called LfcinB 17-31), and another that is a reduced version thereof (called LfcinB20-25), which are derived from bovine lactoferrin, as effective inhibitors of the angiotensin converting enzyme (ACE). The peptides that are the subject of the patent may be obtained chemically, enzymatically or biotechnologically and give rise to peptides with in vitro and/or ex vivo angiotensin converting enzyme inhibitory activity measured as the reduction in the contraction of rabbit carotid arteries induced by exposure to angiotensin 1. These nutraceutical products, possibly in the form of bioactive peptides, are useful both in the food industry and in the pharmaceutical industry. Mejora de la patente peptidos derivados de una proteína láctea con actividad inhibidora de la enzima conversora de angiotensina I. La invención consiste en la utilización de un hidrolizado de lactoferrina que contiene los productos bioactivos derivados de las proteínas lácteas. Se trata de un péptido de quince residuos de aminoácidos (llamado LfcinB17 31), y de otro que es una versión reducida del mismo (llamado LfcinB20 25), derivados de la lactoferrina bovina como inhibidores efectivos de la enzima conversora de la angiotensina (ECA). Los péptidos objetos de la patente obtienen enzimáticamente y dan lugar a péptidos con actividad inhibidora de la enzima convertidora de la angiotensina in vitro y/o ex vivo, midiendo la disminución de la contracción de arterias carótidas de conejo inducida por exposición a angiotensina I. Estos productos nutracéuticos, ya sea como péptido biactivos, son tanto útiles para la industria alimentaría como para la farmacéutica.